Biotech industry is enjoying a strong IPO resurgence

11/21/2013 | Financier Worldwide magazine

The biotech initial public offering market is experiencing a strong revival this year after several dry years, Richard Summerfield writes. In the first half of 2013 alone, the value of biotech IPOs surpassed $1.7 billion, more than 2011 and 2012 together. Several factors boosted the popularity of biotech IPOs, including the number of drugs approved last year and the adoption of the Jumpstart Our Business Startups Act.

View Full Article in:

Financier Worldwide magazine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC